XXXX associated with @entity5532 therapy.

@entity1 @entity1018 @entity227 @entity5532 @entity417 @entity2359 @entity10775 @entity2319 @entity854 @entity1781 @entity68
We have documented @entity227 in 42 of 89 @entity1 with transfusion-dependent @entity417 who were receiving @entity68 chelation therapy with subcutaneous @entity5532 ( @entity10775 ). Of the affected groups, 13 presented with @entity227 or @entity2319 or both, and ophthalmologic, audiologic, and visual evoked potential studies (VEPs) uncovered @entity854 in 29 more. Four @entity1 with @entity227 had @entity1781 with a marked @entity1018 . These 4, and 16 other asymptomatic @entity1 , had abnormal VEPs. When @entity10775 was stopped, 3 of 4 with visual problems regained normal visual function but VEPs remained abnormal. Of the other 16 with abnormal VEPs, 9 became normal or improved and 7 did not change; on restarting @entity10775 , the 9 became abnormal again. There were 22 abnormal audiograms that showed a high-frequency sensorineural deficit; 13 @entity1 were symptomatic and 4 needed hearing aids. On stopping @entity10775 , 9 became asymptomatic but 15 audiograms remained abnormal and 2 deteriorated further on restarting the drug. An analysis of the clinical data showed that members of the affected group were younger, had lower serum ferritin values, and were self-administering higher doses of @entity10775 /kg body weight. Significantly lower doses of @entity10775 were being taken by @entity1 without @entity854 than by those with visual symptoms, abnormal audiograms, or prolonged VEPs (P less than 0.001, less than 0.006, and less than 0.04, respectively). The data implicate high-dose @entity10775 as a central factor in the pathogenesis of the @entity2359 . Our serial studies provide the basis for effective yet safe @entity10775 administration for @entity1 who require the agent.
